Small cell carcinoma of bladder: A single-center prospective study of 25 cases treated in analogy to small cell lung cancer

Bex, Axel; Nieuwenhuijzen, Jakko A.; Kerst, Martijn; Pos, Floris J.; Boven, Hester van; Meinhardt, W.; Horenblas, Simon

doi:10.1016/j.urology.2004.09.049

Cited by 98 publications

(102 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However this should be interpreted with caution as the good performance status needed for cisplatin based chemotherapy may bias the results associating cisplatin with improved survival. Bex et al in his study reported a median survival period of 15 months in patients who received chemotherapy regardless of the tumor stage compared to 4 months median survival period in patients not on chemotherapy (Bex et al, 2005). While considering treatment options for mixed SCCB i.e.…”

Section: Discussionmentioning

confidence: 99%

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Chhabra

Hegde

Singhal³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Primary small cell carcinoma of urinary bladder is a rare but aggressive disease with poor prognosis and a high mortality rate. It accounts for less than 1 % of all the primary cancers seen in the urinary bladder. Diagnosis and management of this entity poses a challenge to the clinician due to the lack of a standardized protocol for its treatment. Herein we discuss primary small cell carcinoma of the urinary bladder in its entirety.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Chhabra

Hegde

Singhal³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The second most common approach to treat LD was combined chemotherapy and radiation ( Table 2, Table 3). Both (chemotherapy+surgery and chemotherapy+radiation) resulted in a clinical response and/or downstaging of disease: 57% for neoadjuvant chemotherapy in the retrospective analysis by Siefker-Radtke and colleagues; 29 78% in the phase II study done by the same authors, 31 and 100% and 85% for chemoradiation in the retrospective study 38 and prospective study by Bex and colleagues, 28 respectively.…”

Section: Treatment Of Limited Diseasementioning

confidence: 99%

“…14,22,23,25 However, the natural history of SCCB is more aggressive and is associated with poorer prognosis than UCB. Therefore, in most cases, SCCB will be locally advanced or metastatic [20][21][22][23][26][27][28][29] at diagnosis and follow a pattern of metastases similar to UCB. The most common sites of spread are regional and distant lymph nodes, liver and bones.…”

Section: Epidemiology/presentationmentioning

confidence: 99%

“…20,22,23 However, SCCB more commonly coexists with other histologies, such as urothelial carcinoma, adenocarcinoma, squamous cell carcinoma and sarcomatoid-urothelial carcinoma. 20,28,38 Patients with a small cell component to their bladder tumour have a worse clinical outcome than patients with conventional UCB. 15,29,24,39 In addition, patients with a pure SCCB have a median overall survival for nonmetastatic, metastatic or recurrent disease (4.5-9.5 months) that is 2 to 3 times shorter compared to mixed SCCB.…”

Section: Pathological Diagnosismentioning

confidence: 99%

“…68 The only prospective studies were a non-randomized phase II study 31 and a single-centre study of 25 cases treated in a fashion analogous to SCLC. 28 The National Cancer Care Network (NCCN) 69 was the only identified guideline which included SCCB.…”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Moretto

Wood

Emmenegger

et al. 2013

CUAJ

View full text Add to dashboard Cite

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma

et al. 2015

View full text Add to dashboard Cite

To describe the clinical characteristics, treatment patterns and outcomes in advanced small cell bladder cancer (aSCBC) patients and compare to those with urothelial carcinoma (UC). Individuals in the National Cancer Data Base with a diagnosis of either nodal (TxN+M0) or distant metastatic (TxNxM1) disease were identified from 1998 to 2010. We assessed the relationships between stage, treatment modalities and survival in the aSCBC cohort and compared these to UC patients. In the 960 patient aSCBC cohort (62% M1), 50% received palliative therapy alone, 68% in M1 versus 21% in M0 groups (P < 0.0001). Single modality local therapy (15%) and surgical (21%) or radiation‐based (14%) multimodal therapy (MMT) were used in the other 50%. Cystectomy‐based MMT was utilized in 45% of N+M0 versus 6.4% of NxM1 patients (P < 0.0001). Median overall survival (OS) for aSCBC patients was 8.6 months; 13.0 months in N+M0 versus 5.3 months in NxM1 patients (P < 0.0001). Survival was similar between TxN1M0 and TxN2‐3M0 patients (14.8 months vs. 12.1 months, P = 0.15). Urothelial carcinoma patients (n = 27,796, 45% M1) lived longer compared to aSCBC patients in the N+M0 group (17.3 months vs. 13.0 months, P = 0.0007). There were not clinically significant differences in OS between UC and aSCBC patients in the M1 group. Advanced SCBC is a rare disease with a poor survival and palliative therapy is common, especially in M1 patients. In comparison to UC, the outcomes for aSCBC patients are worse in those with lymph node only involvement but similar in those with distant disease.

show abstract

Small cell carcinoma of bladder: A single-center prospective study of 25 cases treated in analogy to small cell lung cancer

Cited by 98 publications

References 25 publications

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Primary Small Cell Carcinoma of the Urinary Bladder - Mini-review of the Literature

Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)

Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma

Contact Info

Product

Resources

About